Don't Use the New Oral Antiplatelet Drug Zontivity Alone

August 2014

You'll hear controversy about the new oral antiplatelet drug, Zontivity (zon-TIV-i-tee, vorapaxar).

It's the first protease-activated receptor-1 (PAR-1) antagonist...and inhibits platelet aggregation for about 4 weeks.

Zontivity is approved for use with low-dose aspirin and/or clopidogrel after a heart attack or in patients with peripheral artery disease...to further reduce CV events or death.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber Insights: APRN includes:

Cutting-edge advice about new medications and how they fit into practice
Unbiased, evidence-based, 100% free of financial support from the pharma industry written by your peers
Side-by-side comparisons of drugs by class or disease state, plus FAQs, pros/cons, and simple recommendations

Subscribe Today!

Already a subscriber? Log in

Volume pricing available. Get a quote

Infectious Diseases Watch For NEW Antibiotics for Skin Infections
Measles Identify Patients Who Could Benefit From Measles Vaccination
Diabetes Consider a GLP-1 Agonist for Diabetic Patients on 2 or 3 Oral Meds
Pediatrics Consider Adding Special Notes on Kids' Quinolone Rxs
Benzodiazepines Help Patients Taper Off Benzodiazepines
Neurology & Pain Test Patients With Memory Loss
Sleep Disorders Avoid Sedatives With Sleep Apnea
Fungal Infections Suggest Topical Jublia for Patients Who Can't Use Oral Terbinafine
Infectious Diseases Help Avoid Serious Interactions With Long-Term Antibiotics
Opioids Alert Patients About Changes to Their Tramadol Rxs
Diabetes Use Pioglitazone for Most Patients...if a Glitazone is Needed
Cardiology Don't Use the New Oral Antiplatelet Drug Zontivity Alone
Antiepileptics Watch for Three New Antiepileptics
Practice Caution Patients About Flammable Meds

Don't Use the New Oral Antiplatelet Drug Zontivity Alone

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Table of Contents